🏛️ Verified NIH Record • Updated 2026-06-30

Study of CG0070 After Transurethral Resection in Patients With IR NMIBC (NCT06253845)

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: H. Lee Moffitt Cancer Center and Research Institute

🩺 Plain-English Summary (8th-Grade Level)

Investigators will evaluate the safety of CG0070 for the treatment of patients with Intermediate-Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC).

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (18 items) and avoid the listed exclusions (34 items).

Location: Moffitt Cancer Center — Tampa, Florida

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • Exclusion Criteria:
  • Current or prior evidence of high-risk NMIBC defined as:
  • HG T1
  • Any recurrent HG (G3) Ta
  • HG Ta \> 3 cm (or multifocal)
  • Any CIS
  • Any BCG exposure in HG patient
  • Any variant histology
  • Any LVI
  • Any HG prostatic urethral involvement
  • Disease that is unable to be completely resected
  • Lack of marker lesion

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

  • Moffitt Cancer Center — Tampa, Florida

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
🏛️ View Official NIH Record ↗